Evidence map›Paper›PMID 35588782›Full record

ArticleExperimental eye research2022

Evaluation of CRISPR/Cas9 mediated TGIF gene editing to inhibit corneal fibrosis in vitro.

Ratnakar Tripathi, Nishant R Sinha, Duraisamy Kempuraj, Praveen K Balne, James R Landreneau, Ankit Juneja, Aaron D Webel, Rajiv R Mohan

Open access · greenAbstract read
In one paragraph

Article in Experimental eye research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Wound healing and signaling pathways.Open life sciences · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ratnakar TripathiHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA; One-Health One-Medicine Ophthalmology and Vision Research Center, Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA.
Nishant R SinhaHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA; One-Health One-Medicine Ophthalmology and Vision Research Center, Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA.
Duraisamy KempurajHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA; One-Health One-Medicine Ophthalmology and Vision Research Center, Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA.
Praveen K BalneHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA; One-Health One-Medicine Ophthalmology and Vision Research Center, Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA.
James R LandreneauHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA; Mason Eye Institute, University of Missouri, Columbia, MO, USA.
Ankit JunejaOne-Health One-Medicine Ophthalmology and Vision Research Center, Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA.
Aaron D WebelHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA; Mason Eye Institute, University of Missouri, Columbia, MO, USA.
Rajiv R MohanHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA; One-Health One-Medicine Ophthalmology and Vision Research Center, Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA; Mason Eye Institute, University of Missouri, Columbia, MO, USA. Electronic address: MohanR@health.missouri.edu.
Harry S. Truman Memorial Veterans' Hospital · USUniversity of Missouri · USUniversity of Missouri Hospital · US

Funding

Gene Therapy in the CorneaR01EY017294 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2007 to 2018
$4.3M
Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur MustardU01EY031650 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2020 to 2024
$3.7M
Novel approaches for corneal haze/fibrosis eliminationR01EY030774 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2019 to 2022
$1.5M
BLRD VA I01 BX000357BLRD VA IK6 BX005646NEI NIH HHS R01 EY017294NEI NIH HHS R01 EY030774NEI NIH HHS U01 EY031650
6 · The paper itself

Abstract

Corneal wound healing is influenced by many factors including transcriptional co-repressors and co-activators. Interactions of co-activators and co-repressors with Smads influence mechanistic loop facilitating transcription of alpha-smooth muscle actin (α-SMA), a key profibrotic gene, in corneal repair. The role of a transcriptional repressor, 5'TG3'-interacting factor (TGIF), in the regulation of α-SMA and myofibroblast formation in the cornea was shown previously by our group. This study tested a hypothesis if TGIF1 gene editing via CRISPR/Cas9 can ease myofibroblast formation in the cornea using an in vitro model. Primary human corneal stromal fibroblasts (hCSFs) generated from donor corneas received gene-editing plasmid facilitating loss (CRISPR/Cas9 knockout) or gain (CRISPR activation) of TGIF function by UltraCruz transfection reagent. Phase-contrast microscopy, immunoblotting, immunocytochemistry and quantitative polymerase chain reaction (qPCR) were used to measure levels of myofibroblast profibrotic genes (α-SMA, fibronectin, Collagen-I, and Collagen-IV) in hCSFs lacking or overexpressing TGIF1 after growing them in± transforming growth factor beta1 (TGF-β1) under serum-free conditions. The CRISPR-assisted TGIF1 activation (gain of function) in hCSFs demonstrated significantly decreased myofibroblast formation and messenger ribonucleic acid (mRNA) and protein levels of profibrotic genes. Conversely, CRISPR/Cas9-assisted TGIF knockdown (loss of function) in hCSFs demonstrated no significant change in the levels of myofibroblast formation or profibrotic genes under similar conditions. These results suggest that TGIF gene-editing approach can be employed to modulate the transcriptional activity of α-SMA in controlling pathological and promoting physiological wound healing in an injured cornea.

Indexed as

Corneal DiseasesGene EditingActinsCell DifferentiationCells, CulturedCollagenCo-Repressor ProteinsCRISPR-Cas SystemsFibroblastsFibrosisHomeodomain ProteinsHumansMyofibroblastsRepressor ProteinsTranscription FactorsTransforming Growth Factor beta1ActinsCollagenCo-Repressor ProteinsHomeodomain ProteinsRepressor ProteinsTGIF1 protein, humanTranscription FactorsTransforming Growth Factor beta1Corneal fibrosisCRISPR/Cas9FibroblastsMyofibroblast differentiationTransforming growth factor β1

Identifiers

PMID35588782
PMCPMC11926991
OpenAlexW4280492637

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.